OTCMKTS:ANTH

Anthera Pharmaceuticals Competitors

$0.06
-0.01 (-13.80 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.06
Now: $0.06
$0.07
50-Day Range
$0.06
MA: $0.08
$0.15
52-Week Range
$0.01
Now: $0.06
$0.19
Volume11,923 shs
Average Volume194,784 shs
Market Capitalization$864,932.50
P/E RatioN/A
Dividend YieldN/A
Beta2.19

Competitors

Anthera Pharmaceuticals (OTCMKTS:ANTH) Vs. VGLS, INNVD, IMNPQ, CAPS, RSPI, and VVUSQ

Should you be buying ANTH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Anthera Pharmaceuticals, including VG Life Sciences (VGLS), Innovus Pharmaceuticals (INNVD), Immune Pharmaceuticals (IMNPQ), Capstone Therapeutics (CAPS), RespireRx Pharmaceuticals (RSPI), and VIVUS (VVUSQ).

VG Life Sciences (OTCMKTS:VGLS) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Volatility and Risk

VG Life Sciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.

Profitability

This table compares VG Life Sciences and Anthera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VG Life SciencesN/AN/AN/A
Anthera PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares VG Life Sciences and Anthera Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VG Life SciencesN/AN/AN/AN/AN/A
Anthera PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for VG Life Sciences and Anthera Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VG Life Sciences0000N/A
Anthera Pharmaceuticals0000N/A

Summary

Anthera Pharmaceuticals beats VG Life Sciences on 1 of the 1 factors compared between the two stocks.

Innovus Pharmaceuticals (OTCMKTS:INNVD) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Earnings & Valuation

This table compares Innovus Pharmaceuticals and Anthera Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innovus Pharmaceuticals$23.99 million0.00$-8,280,000.00($4.16)N/A
Anthera PharmaceuticalsN/AN/AN/AN/AN/A

Anthera Pharmaceuticals has lower revenue, but higher earnings than Innovus Pharmaceuticals.

Analyst Recommendations

This is a summary of current ratings and target prices for Innovus Pharmaceuticals and Anthera Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innovus Pharmaceuticals0000N/A
Anthera Pharmaceuticals0000N/A

Volatility and Risk

Innovus Pharmaceuticals has a beta of 2.89, indicating that its stock price is 189% more volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.

Profitability

This table compares Innovus Pharmaceuticals and Anthera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innovus Pharmaceuticals-34.51%-682.54%-78.57%
Anthera PharmaceuticalsN/AN/AN/A

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 16.4% of Innovus Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Anthera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Innovus Pharmaceuticals beats Anthera Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Anthera Pharmaceuticals (OTCMKTS:ANTH) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares Anthera Pharmaceuticals and Immune Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anthera PharmaceuticalsN/AN/AN/AN/AN/A
Immune PharmaceuticalsN/AN/AN/AN/AN/A

Volatility and Risk

Anthera Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Anthera Pharmaceuticals and Immune Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anthera Pharmaceuticals0000N/A
Immune Pharmaceuticals0000N/A

Profitability

This table compares Anthera Pharmaceuticals and Immune Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anthera PharmaceuticalsN/AN/AN/A
Immune PharmaceuticalsN/AN/AN/A

Summary

Anthera Pharmaceuticals beats Immune Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Capstone Therapeutics (OTCMKTS:CAPS) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Capstone Therapeutics and Anthera Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$2 million1.42$-380,000.00N/AN/A
Anthera PharmaceuticalsN/AN/AN/AN/AN/A

Anthera Pharmaceuticals has lower revenue, but higher earnings than Capstone Therapeutics.

Risk and Volatility

Capstone Therapeutics has a beta of 176.15, indicating that its share price is 17,515% more volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.

Profitability

This table compares Capstone Therapeutics and Anthera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Capstone TherapeuticsN/AN/AN/A
Anthera PharmaceuticalsN/AN/AN/A

Institutional & Insider Ownership

2.6% of Capstone Therapeutics shares are owned by institutional investors. 42.8% of Capstone Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Anthera Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Capstone Therapeutics and Anthera Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Capstone Therapeutics0000N/A
Anthera Pharmaceuticals0000N/A

Summary

Capstone Therapeutics beats Anthera Pharmaceuticals on 4 of the 4 factors compared between the two stocks.

Anthera Pharmaceuticals (OTCMKTS:ANTH) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Anthera Pharmaceuticals and RespireRx Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anthera Pharmaceuticals0000N/A
RespireRx Pharmaceuticals0000N/A

Earnings & Valuation

This table compares Anthera Pharmaceuticals and RespireRx Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anthera PharmaceuticalsN/AN/AN/AN/AN/A
RespireRx PharmaceuticalsN/AN/A$-2,120,000.00N/AN/A

Volatility and Risk

Anthera Pharmaceuticals has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, RespireRx Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares Anthera Pharmaceuticals and RespireRx Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anthera PharmaceuticalsN/AN/AN/A
RespireRx PharmaceuticalsN/AN/A-3,387.16%

Summary

Anthera Pharmaceuticals beats RespireRx Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

VIVUS (OTCMKTS:VVUSQ) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Institutional and Insider Ownership

7.3% of VIVUS shares are held by institutional investors. 12.0% of VIVUS shares are held by company insiders. Comparatively, 2.1% of Anthera Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for VIVUS and Anthera Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VIVUS0000N/A
Anthera Pharmaceuticals0000N/A

Valuation & Earnings

This table compares VIVUS and Anthera Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04
Anthera PharmaceuticalsN/AN/AN/AN/AN/A

Anthera Pharmaceuticals has lower revenue, but higher earnings than VIVUS.

Volatility and Risk

VIVUS has a beta of -3.25, indicating that its stock price is 425% less volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.

Profitability

This table compares VIVUS and Anthera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VIVUS-39.28%N/A-12.18%
Anthera PharmaceuticalsN/AN/AN/A


Anthera Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01-0.0%$3.36 millionN/A0.00Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14-0.0%$2.88 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01-0.0%$2.85 million$2 million0.00
RespireRx Pharmaceuticals logo
RSPI
RespireRx Pharmaceuticals
0.5$0.04-0.8%$2.82 millionN/A-0.09News Coverage
Gap Up
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.45-9.0%$1.87 millionN/A0.00Gap Up
NSPX
Inspyr Therapeutics
0.5$0.01-0.0%$1.83 millionN/A0.00Gap Up
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04-1.4%$1.78 million$530,000.000.00Gap Up
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02-0.0%$1.70 million$20,000.00-0.77
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.45-9.0%$1.57 millionN/A0.00News Coverage
Gap Up
Cardax logo
CDXI
Cardax
0.0$1.95-2.6%$1.55 million$710,000.000.00High Trading Volume
Gap Up
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
HSTC
HST Global
0.8$0.26-7.7%$1.36 millionN/A0.00Gap Down
WWHC
W World
0.8$4.90-8.2%$1.33 millionN/A0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03-4.0%$1.29 million$8.73 million0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.22-4.5%$1.17 millionN/A0.00Decrease in Short Interest
Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05-0.0%$1.12 millionN/A-0.57Upcoming Earnings
AOXG
Aoxing Pharmaceutical
0.5$0.01-0.0%$991,000.00N/A0.00
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04-0.0%$991,000.00N/A0.00
AOLS
Aeolus Pharmaceuticals
0.8$0.01-0.0%$928,000.00N/A0.00Gap Down
ATRX
Adhera Therapeutics
0.0$0.07-11.1%$872,000.00$250,000.000.00Gap Up
PXYN
Praxsyn
0.6$0.00-0.0%$763,000.00N/A0.00
SPHS
Sophiris Bio
0.1$0.02-0.0%$739,000.00N/A0.00Gap Down
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03-25.3%$547,000.00N/A0.00
TRPXD
Therapix Biosciences
0.0$9.20-0.5%$460,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.15-0.0%$399,000.00N/A0.00
SKVI
Skinvisible
0.7$0.08-0.0%$376,000.00$40,000.000.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02-0.0%$366,000.00N/A0.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01-0.0%$343,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00Gap Up
WDBG
Woodbrook Group
0.0$1.60-0.0%$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.10-20.0%$183,000.00N/A0.00Gap Down
PZRXQ
PhaseRx
0.2$0.02-0.0%$175,000.00N/A0.00
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.01-0.7%$82,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00-0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00-0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00-0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.01-10.3%$7,000.00$110,000.000.00Gap Up
Acusphere logo
ACUS
Acusphere
0.0$0.04-0.0%$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.10-20.6%$0.00N/A0.00Gap Up
AOBI
American Oriental Bioengineering
0.4$1.50-0.0%$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01-0.0%$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01-0.0%$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07-0.0%$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01-0.0%$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49-0.0%$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.